| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Hypocrellin B acts as a photosensitizer and sonosensitizer, generating reactive oxygen species (ROS) upon light or ultrasound activation. These ROS induce mitochondrial damage, apoptosis, and inhibit adhesion and migration of cancer cells. It does not have a single defined protein target but rather exerts its effects through photochemical and sonochemical mechanisms.
|
|---|---|
| ln Vitro |
On HepG2 cells, hypocrellin B (2.5 μM, 4 h) causes cytotoxicity 24 hours after sonodynamic treatment (SDT) and triggers early inflammation [2]. Antifungal and antiparasitic properties of hypocrellin B are demonstrated against Leishmania donovani and Candida albicans (IC50: 5 and 12.7 μg/mL) [3].
Hypocrellin B has sonodynamic action to induce mitochondrial damage, survival inhibition, apoptosis, and inhibit adhesion and migration of cancer cells. As a photosensitizer, it generates ROS upon light activation, leading to cell death. It also has antimicrobial and antileishmanial activities. |
| ln Vivo |
Although Hypocrellin B nanoparticles have a stronger anti-cancer impact than Hypocrellin B (2 mg/kg, intravenous injection), it can still limit the formation of A549 tumor-bearing tumors [4].
Specific in vivo activity data for Hypocrellin B are not detailed. As a photosensitizer, it would be expected to have antitumor activity in vivo when activated by light. However, specific animal model studies are not described in the available literature. |
| Enzyme Assay |
The in vitro assay for Hypocrellin B's photosensitizing activity involves measuring its ability to generate ROS upon light activation. Cells or cell-free systems are treated with Hypocrellin B and exposed to light, and the production of ROS is measured using fluorescent probes. The cytotoxic effects are assessed by measuring cell viability.
|
| Cell Assay |
Specific in vitro cell-based assay protocols for Hypocrellin B are not detailed. Its anticancer activity can be assessed in cancer cell lines by treating cells with Hypocrellin B, with or without light activation, and measuring cell viability, apoptosis, and other endpoints. Its antimicrobial activity can be assessed in bacterial or Leishmania cultures.
|
| Animal Protocol |
Specific in vivo animal model protocols for Hypocrellin B are not described. To evaluate its in vivo efficacy, Hypocrellin B could be administered to tumor-bearing mice, followed by light exposure to the tumor site. Tumor growth inhibition would be measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Hypocrellin B are not reported in the available literature. As a photosensitizer, its distribution and clearance are important for its therapeutic efficacy. Studies would be needed to determine its bioavailability, tissue distribution, and half-life.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Hypocrellin B are not available. As a photosensitizer, its toxicity may be related to off-target ROS generation. Toxicity studies would be required to determine its safety margin.
|
| References |
|
| Additional Infomation |
Hypocrellin B is a naphthone compound. Hypocrellin B has been reported and data are available in Shiraia bambusicola. See also: Hypocrellin C (note moved here).
Hypocrellin B is a natural product with potential applications in photodynamic therapy of cancer. Its ability to act as a photosensitizer and sonosensitizer makes it a compound of interest for developing new cancer therapies. It is not an approved therapeutic agent. |
| Molecular Formula |
C30H24O9
|
|---|---|
| Molecular Weight |
528.5062
|
| Exact Mass |
528.142
|
| CAS # |
123940-54-5
|
| PubChem CID |
1023768
|
| Appearance |
Brown to black solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
893.8±65.0 °C at 760 mmHg
|
| Melting Point |
261-263℃
|
| Flash Point |
301.4±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.733
|
| LogP |
5.57
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
39
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C2=C3C4=C(C1)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC)C(=O)C
|
| InChi Key |
SBMXTMAIKRQSQE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H24O9/c1-10-7-12-18-23-19(27(34)29(12)38-5)13(32)8-15(36-3)21(23)22-16(37-4)9-14(33)20-25(22)24(18)26(17(10)11(2)31)30(39-6)28(20)35/h8-9,34-35H,7H2,1-6H3
|
| Chemical Name |
12-acetyl-9,17-dihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,12,16,18(23),20-decaene-7,19-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~3.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8921 mL | 9.4606 mL | 18.9211 mL | |
| 5 mM | 0.3784 mL | 1.8921 mL | 3.7842 mL | |
| 10 mM | 0.1892 mL | 0.9461 mL | 1.8921 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
